Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. The company also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. The company also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. The company is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.